Short Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Decreases By 7.9%

Keros Therapeutics, Inc. (NASDAQ:KROS) saw a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 2,220,000 shares, a drop of 7.9% from the October 31st total of 2,410,000 shares. Based on an average daily volume of 370,500 shares, the days-to-cover ratio is presently 6.0 days.

Hedge Funds Weigh In On Keros Therapeutics

Several large investors have recently modified their holdings of KROS. Assenagon Asset Management S.A. bought a new stake in Keros Therapeutics during the 2nd quarter valued at about $1,118,000. Bank of New York Mellon Corp raised its holdings in Keros Therapeutics by 18.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock worth $5,410,000 after acquiring an additional 18,755 shares during the last quarter. SG Americas Securities LLC bought a new position in Keros Therapeutics in the 2nd quarter valued at approximately $532,000. American Century Companies Inc. boosted its stake in Keros Therapeutics by 24.9% during the 2nd quarter. American Century Companies Inc. now owns 298,170 shares of the company’s stock valued at $13,626,000 after purchasing an additional 59,364 shares during the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Keros Therapeutics in the 3rd quarter worth $603,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Jefferies Financial Group started coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating on the stock. Scotiabank began coverage on shares of Keros Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $84.00 target price on shares of Keros Therapeutics in a research note on Thursday, November 7th. Bank of America lowered their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Twelve analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $88.89.

Keros Therapeutics Stock Performance

Shares of KROS opened at $62.28 on Wednesday. The firm’s 50-day simple moving average is $59.67 and its two-hundred day simple moving average is $52.37. Keros Therapeutics has a fifty-two week low of $27.31 and a fifty-two week high of $73.00. The stock has a market cap of $2.52 billion, a PE ratio of -11.95 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $0.39 million for the quarter. During the same period last year, the firm earned ($1.33) EPS. The company’s revenue was up 4750.0% compared to the same quarter last year. Equities research analysts predict that Keros Therapeutics will post -5.28 EPS for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.